T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
作者： Henry G. Kaplan , Judith A. Malmgren , Mary Atwood
DOI: 10.1111/J.1524-4741.2009.00789.X
关键词:
摘要: … An online prognostic tool is available for calculating risk of disease recurrence in … recurrence risk and pattern of recurrence specific to a cohort of TriNeg T1N0 breast cancer patients by T…
sci-hub.se 参考文章(20)
Peter M. Ravdin, Laura A. Siminoff, Greg J. Davis, Mary Beth Mercer, Joan Hewlett, Nancy Gerson, Helen L. Parker, Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer Journal of Clinical Oncology. ,vol. 19, pp. 980- 991 ,(2001) , 10.1200/JCO.2001.19.4.980
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, J Rolski, A Chan, J Mackey, M Liu, T Pinter, V Valero, C Falkson, T Fornander, T Shiftan, S Olsen, M Buyse, T Kiskartalyi, V Landreau, V Wilson, M Press, J Crown, BCIRG006 Investigators, Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. Cancer Research. ,vol. 69, pp. 62- 62 ,(2009) , 10.1158/0008-5472.SABCS-09-62
PATRICIA M. GRAMBSCH, TERRY M. THERNEAU, Proportional hazards tests and diagnostics based on weighted residuals Biometrika. ,vol. 81, pp. 515- 526 ,(1994) , 10.1093/BIOMET/81.3.515
Virginia Kaklamani, A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX Expert Review of Molecular Diagnostics. ,vol. 6, pp. 803- 809 ,(2006) , 10.1586/14737159.6.6.803
Katrina R. Bauer, Monica Brown, Rosemary D. Cress, Carol A. Parise, Vincent Caggiano, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. ,vol. 109, pp. 1721- 1728 ,(2007) , 10.1002/CNCR.22618
Henry G. Kaplan, Judith A. Malmgren, Impact of Triple Negative Phenotype on Breast Cancer Prognosis Breast Journal. ,vol. 14, pp. 456- 463 ,(2008) , 10.1111/J.1524-4741.2008.00622.X
Lisa Rydén, Göran Landberg, Olle Stål, Bo Nordenskjöld, Mårten Fernö, Pär-Ola Bendahl, HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Research and Treatment. ,vol. 109, pp. 351- 357 ,(2008) , 10.1007/S10549-007-9660-2
Lida Mina, Sharon E. Soule, Sunil Badve, Fredrick L. Baehner, Joffre Baker, Maureen Cronin, Drew Watson, Mei-Lan Liu, George W. Sledge, Steve Shak, Kathy D. Miller, Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue Breast Cancer Research and Treatment. ,vol. 103, pp. 197- 208 ,(2007) , 10.1007/S10549-006-9366-X
B. Fisher, J.-H. Jeong, S. Anderson, N. Wolmark, Treatment of Axillary Lymph Node–Negative, Estrogen Receptor–Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials Journal of the National Cancer Institute. ,vol. 96, pp. 1823- 1831 ,(2004) , 10.1093/JNCI/DJH338
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N Hortobagyi, Lajos Pusztai, None, Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Journal of Clinical Oncology. ,vol. 26, pp. 1275- 1281 ,(2008) , 10.1200/JCO.2007.14.4147